BioSpace Says Verseon Is "Changing the Paradigm of Drug Discovery"
“What sets Verseon apart is its use of molecular
physics modeling to enable the atomic-level engineering of new molecules.”
Why AI Alone Cannot Find Tomorrow’s Medicines
“AI is good at interpolating features within the
bounds of a
well-explored pool of training data but unable to make useful
extrapolations far outside it."
Impact Wealth Magazine Hails Verseon as the Company
Redefining Delay, Prevention, and Treatment of Disease
"Between its
regulated pharmaceuticals and consumer healthspan products, Verseon
... will likely transform twenty-first century medicine and touch the
lives of everyone on the planet."
Verseon’s Kevin Short Speaks with Pharmaceutical Technology Magazine
About the Utility of Data and AI in Medicinal Chemistry
“As we collect much larger and more complex data sets from increasingly
advanced functionally predictive assays, machine-learning tools could
potentially make medicinal chemistry operations more efficient.”
MarkTechPost Features Verseon in Latest Issue of AI in Healthcare Magazine
Interview with Verseon CEO Adityo covers challenges
in small-molecule drug discovery and what Verseon is doing to address them,
spanning advances in fundamental science and AI.